Diroximel fumarate - Biogen
Alternative Names: ALKS-8700; BIIB-098; VUMERITYLatest Information Update: 26 Feb 2026
At a glance
- Originator Alkermes plc
- Developer Alkermes plc; Biogen
- Class Anti-inflammatories; Fumarates; Pyrrolidines; Small molecules
- Mechanism of Action NF-E2-related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple sclerosis
Most Recent Events
- 16 Feb 2026 Diroximel fumarate is covered by patent protection in Europe
- 28 Mar 2025 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Hong Kong (PO, Capsule)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in New Zealand (PO, Capsule)